Development of an effective AIDS vaccine is critical to the ultimate control of the global HIV-1 epidemic. Evaluation of candidate AIDS vaccines in clinical trials is an essential part of this process and is central to the iterative approach required for improving vaccine immunogens and formulations. In this proposal we will state the goals of the Vanderbilt HIV Vaccine Trials Unit (HVTU), define the current state of AIDS vaccine development and critical scientific challenges and describe our plan for implementing and advancing future trials. The Vanderbilt HVTU application will include a consortium between Vanderbilt University and the Cornell University Research Unit in Haiti (GHESKIO) that will have the capacity to perform Phase I clinical trials of candidate AIDS vaccines and advance selected products to Phase II and Phase Ill evaluation. The investigators have extensive experience in the clinical evaluation of vaccines and also bring basic virology and immunology expertise that will contribute to the scientific leadership involved in developing vaccine immunogens, devising vaccine formulations and delivery vehicles, and evaluating immunogenicity, safety, and efficacy in preclinical studies. The investigators are also involved at the national and international level in defining the ethics of performing domestic and international vaccine trials which will be critical during the expansion of studies into developing countries. The focus of the Vanderbilt HVTU consortium will be on the evaluation of novel vaccines vectors (including Venezuelan Equine Encephalitis virus (VEE), adeno-associated virus (AAV), poxvirus, nucleic acid vaccines, and other constructs), the evaluation of cytokine adjuvants (such as IL-12), and combination regimens that incorporate mucosal immunization. Investigators in the Vanderbilt HVTU consortium are engaged at multiple scientific and policy levels of the AIDS vaccine development process, and involved in both domestic and international efforts to pursue the ultimate goal of preventing HIV- l infection and controlling the AIDS epidemic.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01AI047985-01
Application #
6188866
Study Section
Special Emphasis Panel (ZAI1-HSD-A (M1))
Program Officer
Flores, Jorge E
Project Start
2000-06-01
Project End
2005-05-31
Budget Start
2000-06-01
Budget End
2001-05-31
Support Year
1
Fiscal Year
2000
Total Cost
$2,031,609
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Frey, Sharon E; Peiperl, Laurence; McElrath, M Juliana et al. (2014) Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants. Clin Vaccine Immunol 21:1589-99
Wecker, M; Gilbert, P; Russell, N et al. (2012) Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults. Clin Vaccine Immunol 19:1651-60
Churchyard, Gavin J; Morgan, Cecilia; Adams, Elizabeth et al. (2011) A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One 6:e21225
Spearman, Paul; Kalams, Spyros; Elizaga, Marnie et al. (2009) Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. Vaccine 27:243-9
de Bruyn, Guy; Hudgens, Michael G; Sullivan, Patrick S et al. (2005) Participant retention in clinical trials of candidate HIV vaccines. J Acquir Immune Defic Syndr 39:499-501
Goepfert, Paul A; Horton, Helen; McElrath, M Juliana et al. (2005) High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. J Infect Dis 192:1249-59
Lee, Deborah; Graham, Barney S; Chiu, Ya-Lin et al. (2004) Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160. J Infect Dis 190:903-7
de Bruyn, Guy; Rossini, Anthony J; Chiu, Ya-Lin et al. (2004) Safety profile of recombinant canarypox HIV vaccines. Vaccine 22:704-13
McClure, Cori A; Gray, Glenda; Rybczyk, G Kyle et al. (2004) Challenges to conducting HIV preventative vaccine trials with adolescents. J Acquir Immune Defic Syndr 36:726-33
Derdowski, Aaron; Ding, Lingmei; Spearman, Paul (2004) A novel fluorescence resonance energy transfer assay demonstrates that the human immunodeficiency virus type 1 Pr55Gag I domain mediates Gag-Gag interactions. J Virol 78:1230-42

Showing the most recent 10 out of 13 publications